Nonmyeloablative allogeneic stem cell transplantation (NST) has considerable activity in patients with metastatic renal cell carcinoma (RCC), although there are limited long-term follow-up data. Between February 1999 and May 2003, 18 patients with metastatic RCC underwent 19 matched-sibling NSTs after conditioning with fludarabine and cyclophosphamide with tacrolimus and mycophenolate mofetil as posttransplant immunosuppression. Among the four objective responses, all were partial and have relapsed with a median response duration of 609 days (range, 107-926). All responders are alive at a median of 41 months. Median overall survival for the entire cohort was 14 months. There were four early treatment-related deaths and one late treatment-related death. Eight patients died from progressive disease and five (28%) from treatment-related mortality. Stratifying transplant outcome as early death, intermediate (no response, no early death), or response, the combination of pre-treatment anemia and decreased performance status, was associated with adverse outcome (P ¼ 0.015) and reduced survival (HR 5.4, 95% confidence interval of 1.4 to 21, P ¼ 0.007). Responders demonstrated prolonged survival compared to nonresponders (P ¼ 0.002). NST leads to durable responses in a minority of metastatic RCC patients. Appropriate patient selection is paramount. Anemia and decreased performance status may enable risk stratification.
survival analysis
The sensitivity of renal cell carcinoma (RCC) to immune manipulations has been well established. Cytokines such as interleukin-2 (IL-2) and interferon-alpha elicit responses, as well as occasional compete remissions. [1] [2] [3] The durability of complete responses to IL-2 and the finding of renal cancerspecific tumor-infiltrating lymphocytes in tumor specimens 4 have encouraged ongoing investigation into immunotherapy.
Hematopoietic allogeneic stem cell transplant (HSCT) as a powerful form of immunotherapy has long been exploited for hematologic malignancies. 5, 6 Donor T lymphocytes are thought to mediate a graft-versus-leukemia effect best exemplified by donor lymphocyte infusions leading to complete responses in patients relapsing after HSCT. 7 Reduced intensity preparative regimens allow nonmyeloablative hematopoietic stem cell transplants (NST), which accomplish complete donor engraftment with less acute toxicity and still harness the graft-versus-malignancy effect. NST as a treatment modality for RCC has yielded encouraging early results. Responses occur after complete T-cell donor engraftment and are almost always associated with graft-versus-host disease (GVHD), thus strongly supporting a graft-versus-tumor (GVT) mechanism for the clinical activity. [8] [9] [10] Childs et al 8 pioneered NST for RCC reporting 10 responses among 19 patients. Response rates in subsequent series have generally been lower, varying from 0 to 50% [8] [9] [10] [11] [12] [13] [14] but averaging around 20-25%. There are limited data on response duration, progression after response, and even less insight into causes for the discrepant results. As a modality with appreciable toxicity, methods to enhance the response rates and/or reduce mortality are needed.
Well-developed risk stratification models exist for patients with advanced RCC before and after cytokine therapy. 15, 16 Important adverse factors include performance status o80%, high serum lactate deyhydrogenase, anemia, high corrected serum calcium, and absence of nephrectomy. 15 Other models have identified histologic subtype, number and site of metastases, and age as influencing survival. Poor performance status has uniformly been associated with poor prognosis for advanced RCC. [15] [16] [17] [18] [19] [20] Blaise et al 14 demonstrated pre-transplant progressive disease as an adverse prognostic factor among 57 solid tumor patients undergoing NST. However, we are not aware of data assessing known RCC prognostic factors to patients undergoing NST.
We have previously reported the initial engraftment and response rate for 12 patients undergoing NST for metastatic RCC. 10 We now present the single institutional longterm follow-up of 18 such patients.
Patients and methods
Eligibility and treatment criteria are briefly reiterated here. Additional details have been previously described. 10 
Patients
Eligible patients were 18 to 65 years of age with measurable metastatic RCC who failed immunotherapy. An exemption was obtained for one patient who was 66 years of age at the time of transplantation. Donors were HLA-identical or single HLA locus mismatched siblings. Recipients were required to have an Eastern Cooperative Oncology Group performance status (PS) of o2, a life-expectancy of at least 6 months, and adequate organ function.
Study design
All patients and donors provided the written informed consent to participate in the protocol, which was approved by the University of Chicago institutional review board.
Recipients were conditioned with 30 mg/m 2 of fludarabine intravenously (i.v.) daily for 5 days (total 150 mg/m 2 ) followed by 2 gm/m 2 (total 4 g/m 2 ) of cyclophosphamide i.v. daily for 2 days, except for the first four transplants performed with 3 days of fludarabine (total 90 mg/m 2 ) followed by 1 day of cyclophosphamide (total 2 g/m 2 ). Poor engraftment led to the intensified conditioning regimen. Unmanipulated G-CSF mobilized peripheral blood stem cells were infused after a day of rest. Post-transplant immunosuppression was with tacrolimus from day À1 to day 90 and mycophenolate mofetil (MMF) 1 g twice daily from day 0 to day 60. Early withdrawal of immunosuppression was permitted for disease progression but no adjustments were made based upon chimerism results.
Chimerism
Chimerism was assessed in peripheral whole blood at multiple time points. For sex-mismatched donor/recipient pairs, fluorescence in situ hybridization (FISH) for X and Y chromosomes was used whereas for same sex donor/ recipient pairs, a PCR-based variable number of tandem repeats (VNTR) method was used. 21 Lineage-specific engraftment analysis was performed on some patients.
Response assessment
Response was assessed by computerized tomography (CT) scans on day 30, day 100, day 180, and every 3 months thereafter. A partial response (PR) was defined as a greater than 50% decrease from baseline in the sum of products of perpendicular diameters of all measurable lesions. A complete response required disappearance of any evidence of disease or disease symptoms for more than 4 weeks. Progressive disease (PD) required either a 25% increase or an increase of 10 cm 2 in the sum of products of measurable lesions or the development of any new lesion. All other responses were considered stable disease.
Early death and transplant-related mortality
Early death (ED) was defined as any death resulting from events (infection, toxicity, disease progression) occurring within 100 days of the transplant, including deaths after 100 days where the precipitating event occurred before 100 days. Thus, one patient who died at day 105 was included because the event leading to death occurred before day 100. Transplant-related mortality (TRM) was any death not a result of PD.
Management of post-transplant PD
Patients with PD after transplant were first treated with withdrawal of immunosuppression, if clinically feasible. Additional treatment options were donor lymphocyte infusion (DLI) or interferon-alpha. These were only used if GVHD was controlled and the patient was not receiving immunosuppression. For DLIs, donor lymphocytes were collected from the original stem cell donors as a nonmobilized collection and infused at a dose of 5 Â 10(7) CD3 cells/kg of recipient weight. Additional treatments, such as metastatecomy and systemic interventions, were at the treating physicians' discretion.
Prognostic factors
Several known prognostic factors were explored including anemia (defined as hemoglobin o12 g/dl), Eastern Cooperative Oncology Group performance status (PS), PD within the 3 months prior to transplant, and lactate dehydrogenase (LDH). By protocol, all patients were required to have a PS of 0 or 1. Other adverse factors such as hypercalcemia, histologic subtype, or absence of a nephrectomy were too infrequent for consideration.
Statistical analysis
Since 19 transplants were performed in 18 patients, the denominator used differs depending on the variable of interest. Statistical analysis was performed using the Stata Version 8 software. 22 The Mann-Whitney two-sample rank sum test was used to compare transplant outcomes by pretreatment factor. Fisher's exact test was used for analysis of other categorical variables. Survival analysis was performed from the day of transplant by the method of Kaplan and Meier. Variables influencing survival were testing using a Cox proportional hazard model for both univariate and bivariate regression to obtain hazard ratios (HR) and 95% confidence intervals (CI). Log-rank test was used to assess the relation between predictors and overall survival and generate P-values. The only covariates tested were PS, anemia, LDH, GVHD, and response. Data were analyzed as of March 20, 2004 . Table 1 summarizes characteristics for the 19 transplants performed on 18 patients. Patient 4 received two transplants and is counted twice for variables that may have differed before each transplant, such as number of prior therapies. Only the second transplant is used for survival analysis. All patients were relapsed from, refractory or intolerant to IL-2 and/or interferon except one patient who had refused cytokine therapy, but had received thalidomide. Only patient number 3 previously responded to immunotherapy. Most cancers were predominantly clear cell, except for two patients with papillary histology. The median number of systemic treatments before transplant, excluding radiation therapy, was 2. All patients, save one, had undergone a nephrectomy. The median age was 55 years.
Results

Patient characteristics
Chimerism
Engraftment results for individual patients are shown in Table 2 . Results are rounded to the nearest 5%. Three of the first four patients, who were treated with the lower dose preparative regimen, developed mixed chimerism and eventually lost their grafts despite DLI for two patients. The mean donor chimerism at day 30 and day 100 was 34 and 38% for these first four patients, respectively. Patient 1, who eventually converted to complete donor engraftment, had similar donor chimerism at day 30 and day 100 as the patients who lost their grafts. Interestingly that patient had just failed treatment with temozolomide, an oral alkylating agent. 23 Graft failures prompted an increase in the intensity of the preparative regimen in subsequent patients. Near complete donor engraftment by day 30 (490% donor chimerism) was present in 6/18 (33%) evaluable transplants, with 3/6 (50%) of these patients developing 4grade 1 acute GVHD whereas no other patients had significant acute GVHD (P ¼ 0.025). The median whole blood donor chimerism among all evaluable patients was 60% at day 30.
Responses
The four partial responses were all documented at day 180 scan evaluation, all in the context of extensive chronic GVHD, and all with delayed complete donor chimerism. Three of the four responders were sex-mismatched transplants. All four patients have since progressed but remain alive. The response rate among patients who engrafted and were alive after day 100 was 4/10 (40%).
Course of responders
Patient 1 entered transplant with stable disease. Areas of tumor involvement were the primary renal lesion as well as the lung, lymph nodes, and spleen. He obtained a partial remission by day 190. PD developed while on tacrolimus for extensive chronic GVHD 2 years and 10 months after transplant with growth in the primary kidney lesion and development of a contralateral renal lesion. Debulking nephrectomy was performed. Immunosuppression was completely withdrawn after surgery. Despite remaining off immunosuppression, additional contralateral renal lesions and mediastinal lymph nodes continued to progress. Extracorporeal photophoresis has remarkably improved GVHD, allowing institution of interferon-alpha. The patient has a PS of 1 (PS was 0 before interferon), 19 months after progression and 53 months after transplant.
Patient 4 (second transplant) entered transplant with PD. Pre-transplant disease was found in the lymph nodes, liver, and bone. Early during transplant (day 84), radiation therapy was administered to a rapidly growing paraspinal lymph node/soft tissue mass with bone extension. The mass significantly regressed. Gut GVHD developed on day 104 with steroids and tacrolimus instituted on day 107. A hepatic lesion regressed on day 180 evaluation consistent with a GVT effect. PD occurred in the liver on day 288. A hepatic metastectomy was then performed. Unfortunately, disease recurred in the liver on day 561 and the patient's condition deteriorated. DLI resulted in exacerbation of GVHD. An enlarging malignant pleural effusion confirmed PD. The patient has clinically stabilized with a PS of two 3 years after transplant and 13 months after DLI. He has refused re-evaluation to assess for a delayed response.
Patient 5 entered transplant with progressive disease. Pulmonary nodules constituted the only site of disease. Disease regression was documented on day 185. Chronic GVHD developed on day 118 and required the institution of prednisone therapy. A solitary residual pulmonary nodule eventually progressed on day 1111 while on 20 mg of prednisone daily. This remains the only site of disease. Limited pulmonary reserve from prior pulmonary surgeries, pulmonary infections, pulmonary embolus, and bleomycin exposure has precluded metastectomy. The patient remains alive with extensive chronic skin GVHD, a single site of disease, and PS of one, 44 months after transplant.
Patient 10 entered transplant with SD. Pulmonary nodules and lymphadenopathy constituted the only site of disease. Prior to transplant, the patient had undergone a left nephrectomy, and a right partial nephrectomy, splenectomy and distal pancreatectomy. On day 127, steroids and tacrolimus were started for clinical gut and skin GVHD. On day 174, the pulmonary lesions regressed. PD occurred while on prednisone and MMF for chronic GVHD on day 524 in the right adrenal gland. Exacerbation of chronic GVHD during prednisone tapering prevented further immunosuppressive tapering. However, extracorporeal photopheresis resulted in a dramatic skin response enabling withdrawal of immunosuppression. A right adrenalectomy removed the only site of PD. A DLI was administered on day 1087, resulting in mouth GVHD. Initial restaging showed stable disease. At 3 years and 3 months after transplant, the patient has a PS of 0.
In three of the four patients, the initial site of PD occurred in areas of previous response while in patient 10 the recurrence arose in very close proximity to a prior surgery. All patients thus progressed in sites of prior disease.
Donar lymphocyte infusion
Seven DLIs in six patients were performed. The two DLIs for poor engraftment were ineffective and the patients eventually lost their grafts. Five DLIs among four patients for PD led to two cases of GVHD and no responses, although a clinical benefit might have been obtained in patient 4 as the patient clinically stabilized. The patient has deferred repeat imaging. 
Graft-versus-host disease
Grade 2 or greater acute GVHD occurred in 3/19 (16%) transplants. Among the 10 engrafted patients evaluable for chronic GVHD, seven patients (70%) developed extensive chronic GVHD (cGVHD). Overall, acute GVHD (aGVHD) or cGVHD occurred in 10 patients. GVHD only occurred with complete or near complete whole blood donor chimerism as seen in Table 2 .
ED, TRM, and survival
Among the 19 transplants, six resulted in early deaths. Patient 6 died from sepsis at day 68. Patient 9 died from cerebellar hemorrhage on day 9 with a platelet count of 42 K/uL. An autopsy confirmed the presence of an occult CNS metastasis. Patients 16 and 17 both died from rapidly PD before day 80 without signs of GVHD. Acute gut GVHD either caused or significantly contributed to death for patients 7 and 15, who died on day 105 and day 44, respectively. Both these patients had almost complete donor engraftment by day 30. In all, 13 patients have died, eight (44%) from PD and five (28%) from treatmentrelated causes. Median survival among all 18 patients, excluding the first transplant for patient 4, was 427 days (Figure 1 ). Median follow-up for survivors is 39 months with 1-and 2-year survival and accompanying 95% CI of 55% (0.30, 0.74) and 37% (0.15, 0.58), respectively. Table 3 tabulates prognostic factors for three different transplant outcomes, ED, responders (PR), and intermediate (neither ED nor PR). A trend exists for more frequent anemia and worse PS among the ED subset. When combining these two factors, the difference reaches statistical significance in predicting transplant outcome with a P-value of 0.015. LDH values prior to transplant were not 1.5 times the upper limit of normal in any patient but were above the upper limit of normal in four transplants -two with ED and two other.
Prognostic factors
Anemia showed a trend toward worse survival (HR of 2.6, CI 0.8 to 8.1, P ¼ 0.089) whereas decreased PS was significantly associated with reduced survival (HR of 5.4, CI 1.6 to 18, P ¼ 0.002). When anemia or decreased PS was applied as independent predictors in a bivariate analysis, the results were similar with HRs of 2.5 and 5.3, respectively. In a univariate model, the combination of anemia and/or nonzero PS, correlated with reduced survival (HR of 5.4, CI 1.4 to 20.6, P ¼ 0.007). PD in the 3 months before transplant was not associated with worse survival (P ¼ 0.33) nor was LDH when examined as a continuous variable (P ¼ 0.32). Survival was prolonged in responders (P ¼ 0.002). 
Discussion
We summarize long-term follow-up after NST for RCC and explore prognostic factors. In our updated results, there were four responses in 19 transplants among 18 patients for an overall response rate of 4/18 (22%). Responses were mostly prolonged, with a median response duration of 609 days (range 107-926), and associated with prolonged survival compared to nonresponders (P ¼ 0.002). All four responding patients have relapsed but are alive at a median follow-up of 41 months whereas only 1 of 14 nonresponding patients are alive. Since activity to second-line cytokines after initial cytokine therapy is rare, 24, 25 the durable responses in these cytokine refractory patients offers promise. Nevertheless, patients with good prognostic features have a median survival of 20 months and a 1-year survival of 71%. 15 It is thus not possible to determine whether the observed prolonged survival is due to the treatment. Whether response rates would be higher in cytokine naı¨ve RCC requires prospective testing.
As has been previously reported, rapid donor engraftment was associated with grade 2 or greater aGVHD (P ¼ 0.025). 26 Significant aGVHD correlated with reduced survival (P ¼ 0.028), similar to a large analysis for chronic myeloid leukemia. 27 In contrast, complete donor chimerism for responders was delayed. The data herein raise concern about the potential downside with protocols inducing early complete donor chimerism to optimize responses and reduce tumor tolerance. 9 In most series, GVHD has been highly associated with responses for RCC. This is not apparent from our series. Although all of the responses occurred in the context of cGVHD, none of the responders had aGVHD and many nonresponders with functioning grafts did not develop cGVHD. The presence of three cases of tumor response in the literature without GVHD for RCC suggests that, at least in some cases, GVT may be separate from GVHD. 8, 9, 28 All responding patients progressed and interestingly, they were all on immunosuppression for cGVHD when PD occurred. Three of four patients progressed at sites of prior response. Withdrawal of immunosuppression has been associated with a tumor response. 9 It is therefore conceivable that, at least in some patients, disease progression is facilitated by immune suppression required for management of GVHD. Alternative management strategies for GVHD or more effective GVHD prevention are required to address this problem.
There are limited data overall regarding DLIs for RCC after NST. For diseases highly sensitive to allogeneic transplant, such as chronic phase chronic myelogenous leukemia, DLI has been highly effective. 7 Childs and colleagues found only one response after eight DLIs. We documented no activity after five DLIs among four patients with PD. Response to DLI is thought to relate to T-cell dose, but the presence of cGVHD prevented dose-escalation of DLI.
While most protocols have employed DLI and/or cytokine therapy for PD, nonimmune therapies also should be considered to enhance tumor responsiveness. Pre-clinical data suggest the addition of tumor-infiltrating-lymphocytes may overcome drug resistance in RCC exposed to subtherapeutic drugs. 29 Hence, the addition of cytotoxic therapy in conjunction with NST should be investigated to augment the existing GVT effect.
Counterbalancing the enthusiasm for the durable responses and promising survival is the challenge of modest overall response rate and appreciable early mortality after NST. In our series, six of 19 (32%) transplants resulted in early deaths. Four deaths were nonrelapse related with significant aGVHD contributing to two of these. One of the four deaths occurred from a hemorrhage into a CNS metastasis with a platelet count of 42 K/mL. To what extent disease progression was also a factor is unclear. ED in two other patients was clearly caused by PD. Overall, TRM was 5/18 (28%) and only occurred in one patient who did not die early. The eight other deaths all resulted from PD, most occurring late. Thus, after surviving the initial transplant period, PD remains the major force of mortality.
The long follow-up allowed us to explore prognostic factors for RCC after NST. Models for advanced RCC in the nontransplant setting have detailed many adverse factors. PS has consistently proven to be a strong prognostic factor. 15, [17] [18] [19] [20] Strict patient selection, including a 46 month life-expectancy, limited the variability in adverse factors, except for anemia (Hb o12 g/dl) and PS (either 0 or 1). The limited number of responses impedes identifying factors predictive of response, especially among this fairly homogenous group. However, stratifying groups into ordered categories of ED, intermediate, or PR was informative.
We found anemia and PS 40 were predictive and prognostic. Despite the limited sample size, pre-transplant anemia and/or decreased PS was significantly associated with response group (P ¼ 0.015) and survival (P ¼ 0.007) as shown in Table 3 . The association extends the prognostic utility of anemia and PS to the transplant setting as prior analysis validated these factors in both cytokine naı¨ve and cytokine refractory patients. 15, 16 Prospective validation and exploring other prognostic factors is needed. For now, riskstratifying patients using several simple measures appears a promising method to reduce ED and enrich the population for subjects most likely to respond.
Comparisons among published studies for RCC after NST yield insights into future approaches (Table 4) . Almost all transplant regimens have employed matchedsibling peripherally mobilized donor stem cells administered after conditioning with a fludarabine-based regimen. Post-transplant GVHD prophylaxis protocols have differed slightly and may account for the discordant rates of aGVHD. The mean overall response rate, across series, was 24%, ranging from 0 to 57%. A trend exists for trials with higher response rates to have a higher incidence of aGVHD, supporting the importance of a GVT effect. Moreover, in the only study systematically using T-cell depletion, the response rate was only 8%.
14 Patient selection may also account for the discordant outcomes across series. Our data support the influence of patient selection as two simple pre-transplant factors reflecting health status, anemia, and PS, were associated with worse outcome among uniformly treated patients at a single center. In the absence of detailed patient characteristics, comparing study populations is difficult. Nevertheless, the large response rate variation across series, even among centers using similar regimens, further suggests that patient selection may account for series with higher response rates. This re-emphasizes the importance of physician expertise, not only in the experience in NST but in the ability to select appropriate transplant candidates.
In conclusion, NST for RCC is feasible and may lead to durable responses in a minority of patients. Despite reduced regimen-related toxicity, significant morbidity and mortality ensues. Only patients with a life-expectancy beyond 6 months can possibly benefit from transplant. Prospective validated models for patients undergoing NST are needed for appropriate risk stratification. Our data suggest the presence of adverse prognostic factors previously identified for RCC, including anemia and/or nonzero PS, should prompt close re-evaluation of whether to proceed with NST. Such criteria may restrict the availability of NST for RCC or solid tumors but may conversely offer encouragement to patients and clinicians by ensuring selected patients have a low probability of acute mortality and a reasonable chance of durable response. Moreover, this offers initial guidance in patient selection for approaches such as cooperative group studies or unrelated-donor NST for RCC. In the future, correlative work to elucidate the mechanism(s) of GVT may permit immunologic therapies without the toxicity of transplant. For now, we believe NST for RCC remains a promising approach. 
